Teaching tolerance
Authors:
Open Access
- 16 October 2012
- journal article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (10) , 1459-1464
Abstract
Babies born with Pompe disease require life-long treatment with enzyme-replacement therapy (ERT). Despite the human origin of the therapy, recombinant human lysosomal acid α glucosidase (GAA, rhGAA), ERT unfortunately leads to the development of high titers of anti-rhGAA antibody, decreased effectiveness of ERT, and a fatal outcome for a significant number of children who have Pompe disease. The severity of disease, anti-drug antibody (ADA) development, and the consequences thereof are directly related to the degree of the enzyme deficiency. Babies born with a complete deficiency GAA are said to have cross-reactive immunologic material (CRIM)–negative Pompe disease and are highly likely to develop GAA ADA. Less frequently, GAA ADA develop in CRIM-positive individuals. Currently, GAA-ADA sero-positive babies are treated with a combination of immunosuppressive drugs to induce immunological tolerance to ERT, but the long-term effect of these regimens is unknown. Alternative approaches that might redirect the immune response toward antigen-specific tolerance without immunosuppressive agents are needed. Methods leading to the induction of antigen-specific regulatory T cells (Tregs), using peptides such as Tregitopes (T regulatory cell epitopes) are under consideration for the future treatment of CRIM-negative Pompe disease. Tregitopes are natural T cell epitopes derived from immunoglobulin G (IgG) that cause the expansion and activation of regulatory T cells (Treg). Teaching the immune system to tolerate GAA by co-delivering GAA with Tregitope peptides might dramatically improve the lives of CRIM-negative babies and could be applied to other enzyme replacement therapies to which ADA have been induced.Keywords
This publication has 52 references indexed in Scilit:
- In Vitro and In Vivo Studies of IgG-derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of AutoimmunityJournal of Clinical Immunology, 2012
- Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe DiseaseMolecular Therapy, 2010
- Expression of GARP selectively identifies activated human FOXP3+ regulatory T cellsProceedings of the National Academy of Sciences, 2009
- The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine modelsImmunology, 2009
- Pathobiology of Secondary Immune ThrombocytopeniaSeminars in Hematology, 2009
- Identification of a receptor required for the anti-inflammatory activity of IVIGProceedings of the National Academy of Sciences, 2008
- Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG FcScience, 2008
- Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease modelClinical and Experimental Immunology, 2008
- Enhanced Response to Enzyme Replacement Therapy in Pompe Disease after the Induction of Immune ToleranceThe American Journal of Human Genetics, 2007
- DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotypeProceedings of the National Academy of Sciences, 2006